Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612211 | 0.94 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL27713617 | 0.91 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL27733996 | 0.89 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL732667 | 0.87 | MAPT (0.58) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL578910 | 0.87 | ALDH1A1 (0.67) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL25491034 | 0.85 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL22987103 | 0.84 | CYP1A2 (0.78) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL28529318 | 0.83 | KMT2A (0.57) | ALDH1A1KMT2AKDM4EMEN1POLB | |
| SCHEMBL24992868 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL5925544 | 0.83 | CYP1A2 (0.72) | ALDH1A1CYP1A2CYP2D6SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2003016615-A1 | SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-5972042-A | DYEING SYSTEM WHICH COMPRISES ONE OR MORE MONO-, DI- OR POLYCYCLIC AROMATIC OR HETEROAROMATIC COMPOUNDS, AND HYDROGEN PEROXIDE SOURCE AND ENZYME EXHIBITING PEROXIDASE ACTIVITY OR ENZYME EXHIBITING OXIDASE ACTIVITY | NOVO NORDISK A/S (DE) | 1999-10-26 | — | — | US | disclosed |
| US-5925148-A | TREATING IN AQUEOUS DYE LIQUOR WITH SYSTEM COMPRISING SUBSTITUTED AROMATIC COMPOUND, HYDROGEN PEROXIDE SOURCE AND PEROXIDASE ENZYME AND/OR OXIDASE ENZYME | NOVO NORDISK A/S (DK) | 1999-07-20 | — | — | US | disclosed |
| EP-0870082-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023684-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ALDH1A1 2287/4885CYP1A2 828/4885CYP2D6 381/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | ALDH1A1 664/4885CYP1A2 3182/4885CYP2D6 3993/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | ALDH1A1 664/4885CYP1A2 3182/4885CYP2D6 3993/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | ALDH1A1 530/4885CYP1A2 2904/4885CYP2D6 1922/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | ALDH1A1 664/4885CYP1A2 3182/4885CYP2D6 3993/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | ALDH1A1 530/4885CYP1A2 2904/4885CYP2D6 1922/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | ALDH1A1 983/4885CYP1A2 2592/4885CYP2D6 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.